KRAS and non-small cell lung carcinoma: Some reports have KRas mutations associated with poorer outcomes in NSCLC patients, especially those in early stages, going as far as finding that NSCLC patients with G12C and G12V KRas mutants had significantly reduced progression-free survival compared with those with G12D mutations or WT KRas [265,266].